Sleep and breast and prostate cancer risk in the MCC‑Spain study
Metadatos
Mostrar el registro completo del ítemEditorial
Springer Nature
Fecha
2022-12-16Referencia bibliográfica
Turner, M.C., Gracia-Lavedan, E., Papantoniou, K. et al. Sleep and breast and prostate cancer risk in the MCC-Spain study. Sci Rep 12, 21807 (2022). [https://doi.org/10.1038/s41598-022-25789-9]
Patrocinador
Basque Country; Catalan Government DURSI 2014SGR647, 2014SGR850, 2017SGR1085, 2017SGR723; Consejería de Salud of the Junta de Andalucía PI-0306-2011, PI-0571-2009; Spanish Association Against Cancer; Fundación Bancaria Caja de Ahorros de Asturias; Ministerio de Ciencia, Innovación y Universidades; Eno Scientific Foundation; European Commission FOOD-CT-2006-036224-HIWATE; Fundación Científica Asociación Española Contra el Cáncer; Generalitat de Catalunya; Instituto de Salud Carlos III CIBERESP CB06/02/0073, PI08/1359, PI08/1770, PI09/00773, PI09/01286, PI09/01662, PI09/01903, PI09/02078, PI11/01403, PI11/01889, PI11/02213, PI12/00150, PI12/00265, PI12/00715, PI12/01270, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI17CIII/00034; Ministerio de Ciencia e Innovación CEX2018-000806-S; European Social Fund; Universidad de Oviedo RYC-2017-01892; Consejería de Educación, Junta de Castilla y León LE22A10-2; Conselleria de Sanitat Universal i Salut Pública 2010ACUP 00310, AP_061/10; Fundación Marqués de Valdecilla API 10/09Resumen
Breast and prostate cancers have been associated with circadian disruption. Some previous studies examined associations of sleep duration and breast or prostate cancer risk though findings remain inconsistent. This study examines associations of a range of detailed sleep characteristics and breast and prostate cancer risk in a large-scale population-based case–control study, MCC-Spain. A total of 1738 incident breast cancer cases, 1112 prostate cancer cases and frequency matched controls (n = 1910, and 1493 respectively) were recruited. Detailed data on habitual sleep duration, quality, timing, and daytime napping (“siesta”) were collected at recruitment. Additional data on sleep habits during both the previous year and at age 40 years were also subsequently captured. Adjusted odds ratios (ORs) and 95% confidence intervals (CI) were estimated. There were no associations of habitual sleep duration (h), timing of sleep, or any or specific sleep problems, and either breast and prostate cancer risk. There was a significant positive association of ever taking habitual siestas at recruitment and breast cancer risk (OR = 1.22, 95% CI 1.06–1.42), which strengthened with increased frequency or duration. There were also significant positive associations observed for both breast and prostate cancer, among those reporting recent sleep problems, but not sleep problems at age 40 years, in a subsequent circadian questionnaire. Adverse associations with siesta and disturbed sleep during the previous year likely reflect symptoms of developing/diagnosed cancer and comorbidities. Overall, there was no clear association between various sleep characteristics and breast or prostate cancer risk observed.